Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- pitolisant
- Tukysa (tucatinib)
Interactions between your drugs
pitolisant tucatinib
Applies to: pitolisant, Tukysa (tucatinib)
MONITOR: Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450 3A isoenzymes. When a single 2 mg dose of midazolam, a CYP450 3A substrate, was administered with tucatinib (300 mg twice daily), midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 3-fold and 5.7-fold, respectively. Increased exposure to the CYP450 3A substrate may increase the risk of toxicity.
MANAGEMENT: Caution is advised when tucatinib is used concomitantly with drugs that undergo metabolism by CYP450 3A4. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever tucatinib is added to or withdrawn from therapy.
References (1)
- (2020) "Product Information. Tukysa (tucatinib)." Seattle Genetics Inc
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Lumryz
Lumryz (sodium oxybate) is used for the treatment of patients with narcolepsy. Includes Lumryz side ...
Xywav
Xywav is used for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients ...
Mounjaro
Mounjaro is used for type 2 diabetes to help lower blood sugar levels. Mounjaro has also been shown ...
Sunosi
Sunosi (solriamfetol) is a prescription medicine used for the treatment of excessive sleepiness in ...
Adderall
Adderall (amphetamine and dextroamphetamine) is used to treat narcolepsy and ADHD. Includes side ...
Concerta
Concerta is used to treat attention deficit disorder (ADD) and attention deficit hyperactivity ...
Ritalin
Ritalin (methylphenidate) is used to treat attention deficit disorder (ADD) and narcolepsy ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.